August 01, 2025

Dana-Farber Research News 08.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.

Dana-Farber

July 29, 2025

Esophageal Adenocarcinoma Recurrence Patterns With Perioperative Chemotherapy vs Preoperative Chemoradiotherapy

In an analysis from the German phase III ESOPEC trial reported in the Journal of Clinical Oncology, Hoeppner et al found that perioperative chemotherapy reduced distant recurrence vs preoperative chem...

The ASCO Post

July 29, 2025

Research Leaders Across New York State Form Empire State Cellular Therapy Consortium

To expand on early progress in the emerging field of cell and gene therapy, five research centers across New York State are collaborating to develop new cell therapies for cancer and other diseases.

Roswell Park Comprehensive Cancer Center

July 28, 2025

Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates, Study Finds

Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind stud...

The ASCO Post

July 24, 2025

Does Menopausal Hormone Therapy Increase the Risk of Death in Women With BRCA-Mutated Breast Cancer?

The risk of death does not appear to increase with the use of menopausal hormone therapy in women with early-onset, BRCA-mutated breast cancer who began hormone supplementation after diagnosis, based ...

The ASCO Post

July 24, 2025

Immunotherapy Combination: A Potential New Standard in Triple-Negative Breast Cancer

In the phase III ASCENT-04/KEYNOTE-D19 trial, the combination of the TROP2-directed antibody-drug conjugate sacituzumab govitecan-hziy plus the PD-1 inhibitor pembrolizumab in previously untreated pat...

The ASCO Post

July 24, 2025

Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers

The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the mo...

The ASCO Post

July 24, 2025

Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice

The 2025 ASCO Annual Meeting included the presentation of data from more than 7,000 abstracts and clinical trials set to advance research, uncover findings, and in some cases change the standard of pr...

The ASCO Post

July 23, 2025

HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer

In an individual patient-level meta-analysis reported in The Lancet Oncology, Villacampa et al found that the HER2DX assay risk score was prognostic for event-free survival outcomes in patients with e...

The ASCO Post